ClinConnect ClinConnect Logo
Search / Trial NCT02763618

EEG Theta-Beta Ratio Neurofeedback-training

Launched by LEIDEN UNIVERSITY MEDICAL CENTER · May 4, 2016

Trial Information

Current as of May 30, 2025

Completed

Keywords

Neurofeedback Theta/Beta Ratio Multiple Baseline

ClinConnect Summary

Background Resting state EEG measures can produce useful spectral indices of power in different frequency bands. One robust finding in attention-deficit/ hyperactivity disorder (ADHD) has been increased theta band power (typically 4-7 Hz) relative to beta band power (13-30 Hz) otherwise expressed as the 'theta beta ratio' (TBR; Barry, Clark \& Johnstone, 2003). TBR possibly reflects interactions between subcortical and prefrontal cortical areas in the brain (Schutter \& Knyazev, 2012). A recent study from the Leiden University lab showed that increased TBR was related to less self-reported ...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Elevated theta/beta ratio (higher than median in 3 previously conducted studies) Female gender Age between 19 - 23
  • Exclusion Criteria:
  • History of neurologic or psychiatric disorders History or current use of drugs other than alcohol and nicotine Use of medication that is known to influence the brain/cognition.

About Leiden University Medical Center

Leiden University Medical Center (LUMC) is a prominent academic medical center located in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and high-quality patient care. As a clinical trial sponsor, LUMC focuses on translating scientific discoveries into effective therapies, fostering collaborations between researchers, clinicians, and industry partners. The center is dedicated to conducting rigorous clinical studies across various medical fields, ensuring adherence to ethical standards and regulatory requirements while prioritizing patient safety and outcomes. Through its multidisciplinary approach, LUMC aims to contribute significantly to the understanding and treatment of complex health conditions, driving progress in personalized medicine and improving global health.

Locations

Patients applied

0 patients applied

Trial Officials

Peter Putman, PhD

Principal Investigator

Leiden University, The Netherlands

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials